- Home
- PRAX
as 03-28-2025 4:00pm EST
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 730.1M | IPO Year: | 2020 |
| Target Price: | $123.80 | AVG Volume (30 days): | 527.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -10.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $30.01 - $91.83 | Next Earning Date: | 05-12-2025 |
| Revenue: | $8,553,000 | Revenue Growth: | 249.53% |
| Revenue Growth (this year): | -87.35% | Revenue Growth (next year): | 2780.59% |
Latest Praxis Precision Medicines Inc. News
PRAX Breaking Stock News: Dive into PRAX Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting
GlobeNewswire
24 days ago
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TipRanks
25 days ago
Praxis Precision price target lowered to $85 from $150 at Needham
GlobeNewswire
25 days ago
Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences
MT Newswires
a month ago
Deutsche Bank Adjusts Praxis Precision Medicines Price Target to $65 From $111, Maintains Buy Rating
MT Newswires
a month ago
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
MT Newswires
a month ago
Wedbush Downgrades Praxis Precision Medicines to Underperform From Neutral, Cuts Price Target to $26 From $57; Shares Fall
MT Newswires
a month ago
Top Midday Decliners
Compare PRAX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRAX Praxis Precision Medicines Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.